Episode 45: How Chemists Design Cancer-Targeting Radiopharmaceuticals | Chelators Explained

How do chemists design molecules that safely carry radioactive metals through the body to target cancer cells?In this episode of Concentrating on Chromatography, David sits down with Simona Mastroianni and Marianna Tosato to explore the chemistry behind radiopharmaceuticals — drugs that combine radioactive isotopes with specially designed chelators to diagnose and treat cancer.Their latest research focuses on the theranostic pair lead-203 and lead-212, a powerful combination that enables both imaging and targeted alpha therapy using the same chemical platform. To make this possible, they developed new “molecular cages” that tightly bind lead ions, improving stability, safety, and effectiveness in the body.Along the way, we break down:• What radiopharmaceuticals and theranostics actually mean• Why chelators act like cages for radioactive metals• How chromatography (HPLC/TLC) verifies radiolabeling and purity• How NMR shows metals are truly bound• The path from synthetic chemistry → animal studies → hospitals• Career advice for undergraduate chemists interested in medical and radiochemistryIf you’ve ever wondered how analytical chemistry, inorganic chemistry, and separation science translate into real cancer treatments, this episode connects the dots.Based on their recent publication demonstrating highly stable, efficiently labeled cyclen-based chelators for 203/212Pb radiopharmaceuticals and the full interview discussion .🎧 Perfect for students in:Analytical chemistry • Chromatography • Inorganic chemistry • Radiochemistry • Pharmaceutical sciencesradiopharmaceuticals, lead-212 therapy, theranostics, chelators, chromatography, HPLC, NMR, radiochemistry, cancer drug development, analytical chemistry careers